Curaleaf Defends Acquisition Bid for Aurora with Fact Sheet — Curaleaf Holdings, Inc.

Event summary

Curaleaf issued a fact sheet on September 8, 2026, countering Aurora's criticisms of its acquisition proposal.
Curaleaf's offer includes a 45% premium, representing a 110% premium excluding Aurora's cash on balance sheet.
Aurora has recorded ~C$5 billion in impairments and ~C$130 million in business transformation costs under its current strategy.
Curaleaf generated $447 million in positive operating cash flow since FY21, contrasting with Aurora's negative cash flow.

The big picture

Curaleaf's defense of its acquisition bid highlights the strategic divide between the two cannabis giants. While Curaleaf emphasizes its strong cash flow and premium offer, Aurora's standalone plan faces scrutiny over its track record of impairments and negative cash flow. The outcome will influence the consolidation trend in the cannabis sector and the valuation of U.S.-focused operators amid regulatory uncertainty.

What we're watching

Regulatory Reform: The pace at which U.S. federal cannabis reform progresses will impact Curaleaf's valuation and strategic advantages.
Execution Risk: Whether Curaleaf can successfully integrate Aurora and unlock the proposed synergies.
Governance Dynamics: How Aurora's board and shareholders respond to Curaleaf's counterarguments and potential deal negotiations.